Most income investors know Altria (NYSE: MO) for its yield. Fewer understand exactly how the company keeps funding it while selling fewer cigarettes every year. That mechanism deserves a closer look, because it is the real argument for owning the stock.
In August, Altria increased its quarterly dividend by 4.7% to $1.11 per share, marking the 61st dividend increase in 57 years. The yield now sits near 6%, a figure that attracts income investors but also invites skepticism: how does a company with shrinking unit sales keep writing larger checks?
That skepticism is not unique to tobacco. Verizon faces the same question from income investors doubting whether its cash flow can sustain a large yield under competitive pressure.
The answer is pricing power applied with unusual discipline. In April 2026, PM USA increased the list price of Marlboro and L&M by $0.20 per pack, and raised all other premium cigarette brands by $0.25 per pack. That followed similar increases in January 2026 and October 2025. Three rounds of price hikes in roughly twelve months is not unusual for Altria; it is the blueprint. Volume falls, prices rise faster, and operating income expands anyway.
In Q3 2026, reported diluted EPS rose 7.1% to $1.51 per share, while adjusted operating companies income in smokeable products increased 3.9% to $3.07 billion, with adjusted operating margin expanding 10 basis points to 64.5%. A 64.5% operating margin is not what a business in structural decline looks like. It is what a business with pricing authority over an addicted customer base looks like.
The more uncertain part of the thesis is smoke-free. Nicotine pouches now account for 61.2% of the U.S. oral tobacco category as of Q3 2026, up 5.8 share points year over year. Altria’s on! brand is in that category but fighting for position against entrenched competition. Altria’s smoke-free portfolio includes NJOY e-cigarettes and on! nicotine pouches, and it expects smoke-free net revenue to reach about $5 billion by 2028, roughly double its 2022 base.
That target is ambitious, and progress has been uneven. But income investors should not need the smoke-free transition to succeed completely. In Q3 2026, Altria raised full-year adjusted earnings guidance to $5.66 to $5.74 per share, representing 4.5% to 6% growth from the 2025 base of $5.42. That EPS range comfortably covers the $4.44 annualized dividend, leaving room for the streak to continue even if pouches disappoint.
Altria is not the only income name where the underlying business is doing more work than the yield figure suggests. Several REITs are generating operating momentum that their discounted valuations have not yet reflected.
The risk worth monitoring is not volume decline. Cigarette shipments have been falling for decades and the dividend has still compounded. The real risk is regulatory disruption, specifically FDA actions on pricing or nicotine levels that could break the pricing-power engine entirely. To own Altria today, investors largely have to believe its pricing power, smokeable margins, and shareholder returns can offset steady declines in U.S. cigarette volumes and uneven smoke-free traction.
That is a reasonable bet for a portfolio needing reliable income. The 61st dividend increase in 57 years was not luck. It was price discipline, and that discipline is not going anywhere soon.
